About this trial
This study is looking at a new drug - SCH 532706 - from the new class of CCR5 inhibitors or antagonists.
SCH 532706 is taken twice daily (with a low dose of ritonavir taken once daily) over 10 days. The purpose is to look at how effective the combination is at suppressing HIV as well as how safe and easy it is to take.
Background information
CCR5 inhibitors block the CCR5 co-receptor, one of two chemical doorways that HIV uses to enter and infect the cell (the other is called CXCR4).
CCR5 inhibitors work specifically against CCR5-tropic HIV, but some people have CXCR4-tropic HIV (meaning their strain of HIV uses the other co-receptor) or a dual/mixed-tropic virus (meaning their virus uses both).
Usually, CCR5-tropic HIV predominates during early infection while CXCR4-tropic HIV appears later and is associated with more advanced disease.
Before being treated with a CCR5 inhibitor you need to have a test to determine whether you have the right strain of virus this drug class will affect.
| Official title: | Activity and Safety of SCH 532706 in HIV-1 Infected Subjects |
|---|---|
| What is this trial studying? | New drug |
| Start date: | March 2007 (closed in July 2007) This may be the proposed or expected start date for trials which have not yet started. |
| How many participants will this trial enrol? | 12 The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic. |
| How long is this trial planned to go for? | Participants in this trial will be asked to take the trial drug for 10 days. |
| Who can enrol in this trial? | You may be eligible to participate in this trial if you meet the following criteria:
|
| Links to further information: | |
| Results: | See above link for poster presentation from 15th Conference on Retroviruses and Opportunistic Infections (CROI) 2008 |
| Can I access this treatment other than by enrolling in this trial? | No. |
| Keywords: | CCR5, SCH 532706 |
While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.
- Before making the decision to participate in any clinical research, read our background information.
- Email NAPWA if you have any questions or comments about this trial
- Call the Treataware info line if you need further advice
This factsheet, produced by Positive Life NSW, provides you with information and some questions to ask if you are considering participating in a clinical trial.